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Summary
The effects of the degradation-resistant enkephalin analogs FK 33-824 and metkephamid were determined after systemic and intracerebroventricular (i.c.v.) administration in withdrawn morphine-dependent rhesus monkeys.
Both peptides suppressed completely signs of 12-hr morphine deprivation, as does the prototype mu-receptor agonist morphine.
The peptides were 100 and 2000 times more potent, respectively, after i.c.v. than s.c. injection. Thus, although peptidaseresistant, these compounds have restricted entrance into the central nervous system after systemic administration.
The i.c.v, administration of compounds in rhesus monkeys should prove to be a valuable tool in the study of peptide ligands for opiate receptors.
Centrally acting compounds which are large molecular weight and poorly soluble in lipids have difficulty penetrating the blood-brain barrier (BBB).
Some compounds (e.g., peptides) are in addition rapidly metabolized in peripheral tissues.
Thus, these compounds may be more readily and economically studied by injecting them directly into the cerebroventricular system. This technique is particularly useful when investigating activities of endogenous opioid peptides and their analogs.
rhesus monkeys is a well-established method for determining various activities of opioids in non-human primates. In this procedure, dependent monkeys (3 mg/kg/6 hr) are deprived of two consecutive maintenance doses of morphine.
Single doses of test agents are then administered to the withdrawn animals and their behavior is monitored.
Compounds which act at mureceptors suppress signs of abstinence in morphine-deprived dependent monkeys (i). Very few peptides have been studied, in part, perhaps, due to the presumed rapid systemic degradation and poor central nervous system penetration.
We have now established a procedure for intracerebroventricular (i.c.v.) administration of opioids in rhesus monkeys.
In preparation for 
MATERIALS AND METHODS

Cannulation
Mature morphine-dependent rhesus monkeys weighing 4-6 kg were anesthetized with ketamine and pentobarbital. They were implanted with stainless steel cannula (Plastic Products) directed towards the lateral cerebral ventricle according to the atlas of Snider and Lee (2) .
Standard aseptic and stereotaxic techniques were used. Cannula placements were verified by radiography immediately after surgery and every 6 weeks thereafter.
Anesthetized monkeys were x-rayed before and after injection of metrizamide (15 mg; Winthrop). Only those animals with evidence of dye in the cerebroventricular space were used.
SDS Procedure
Rhesus monkeys maintained on 3 mg/kg morphine sulfate (s.c.) every 6 hr for at least 90 days were deprived of morphine for 12-16 hr.
Single doses of test agents were then administered by s.c. or i.c.v, routes.
The severity of withdrawal was rated at regular intervals by two experienced observers, according to the procedures outlined by Deneau and Seevers (3) and Villarreal (I).
Three to five animals were observed simultaneously. Monkeys were tested at weekly intervals.
Each test agent was given to at least 3 monkeys per dose.
The withdrawal severity scores at each time point were averaged.
Compounds and Injections
FK 33-824 (Sandoz), metkephamid (LY 127623, Eli Lilly) and morphine sulfate (Mallinckrodt) were dissolved in sterile water. Doses refer to the particular salt.
The monkeys are trained to come out of their cages for s.c. injections (0.i ml/kg). They are placed in restraining chairs for i.c.v, injections.
Sterile or aseptic solutions are injected slowly i.c.v, in volumes of 100-500 ul.
RESULTS and DISCUSSION
Metkephamid and FK 33-824 suppressed morphine-abstinence in a dose-related manner following both routes of administration (FIG 1 and 2) . This is in agreement with previous work indicating that metkephamid and FK 33-824 have morphine-like effects (4, 5, 6, 7, 8, 9 The dramatic increase in potency and duration of action of FK 33-824 and metkephamid after i.c.v, injection illustrates the effectiveness of the BBB.
Therefore, enzymatic stabilization is not always sufficient for accurate assessment of peptide efficacy.
We previously found that whereas FK 33-824 and metkephamid share discriminative stimulus properties with morphinelike compounds, they were relatively ineffective as reinforcers after systemic administration in monkeys (5, 7) .
At that time it was suggested that the BBB was responsible for the delayed onset of the discriminative stimulus effect.
It is now apparent that the BBB does inhibit entry of FK 33-824 and metkephamid into the central nervous system, which is required for drug discrimination (i0).
This probably also accounts for the limited reinforcing effects of systemically administered morphine-like peptides.
Assessment of opioid peptide efficacy may be best determined by central administration.
